CD274 and neoplasm: The tumor microenvironment itself has been identified as an important factor in treatment response, with PDL1 expression in biopsy samples already an FDA-approved predictive biomarker and the number and spatial arrangement of tumor infiltrating-cells appearing promising [20, 21].